Alchemia Announces Results For FY 2013 and Progress Across Its Major Assets

Alchemia Announcement link here. • Net profit share from fondaparinux of A$9.6m (US$9.5m) for the financial year • Annual loss for the year of A$4.8m, compared with A$15.1m for the previous year • Cash and receivables at 30 June 2013 of A$25.3m • Phase III trial of HA Irinotecan fully recruited • Collaboration with Merck Serono […]

Pharmaxis Announces Delay to French Pricing for Bronchitol

Pharmaxis press release link here. Pharmaceutical company Pharmaxis (ASX:PXS) today announced it will scale back resources and investments dedicated to the launch of Bronchitol in France due to delays in reaching an agreement with French authorities on a reimbursed price for the cystic fibrosis treatment. Pharmaxis CEO Mr Gary Phillips said, “Negotiations with the French Healthcare […]

Australian Medical Media Release: Simplified PBS Listing for Bronchitol (Pharmaxis)

Pharmaxis press release link here. The Australian government has approved a new, simplified Pharmaceutical Benefits Scheme (PBS) status for Bronchitol in the treatment of cystic fibrosis (CF). Following the successful Pharmaxis application to the Pharmaceutical Benefits Advisory Committee (PBAC) and discussions with the Department of Health and Ageing, the new Bronchitol PBS listing removes the restrictive […]

Biota Pharmaceuticals Announces Changes to Its Board of Directors

Biota Pharmaceuticals press release link here. ATLANTA, Aug. 19, 2013 (GLOBE NEWSWIRE) — Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) (“Biota” or the “Company”), a biopharmaceutical company focused on the discovery and development of anti-infective products to prevent and treat serious and potentially life-threatening infectious diseases, today announced changes to its Board of Directors, including the resignation of Dr. Jeffrey […]

AmpliPhi Presents Data on Bacteriophages in the Treatment of Lung Infections in Cystic Fibrosis

AmpliPhi press release link here. Data presented at the 20th Biennial Evergreen International Phage Meeting, 4-9 August 2013, Evergreen State College, Olympia, WA, USA RICHMOND, Va. & SYDNEY & LONDON–(BUSINESS WIRE)–Aug. 8, 2013– AmpliPhi BioSciences Corp. (OTC: APHB) (“AmpliPhi”), the leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant bacterial infections, yesterday presented data relating to the use of bacteriophages in the […]

AmpliPhi Signs Global R&D Agreement with US Army to Develop Bacteriophage Therapies to Treat Resistant Bacterial Infections

AmpliPhi press release link here. AmpliPhi Signs Global R&D Agreement with US Army to Develop Bacteriophage Therapies to Treat Resistant Bacterial Infections RICHMOND, VA, US, SYDNEY, AUSTRALIA, London UK, July 1, 2013 – AmpliPhi BioSciences Corporation (OTC: APHB) (“AmpliPhi”), the leader in the discovery and development of bacteriophage-based therapies to treat drug resistant bacterial infections, announced […]

BioScience Managers Backs Bioxyne Move

BioScience Managers Pty Ltd (formerly Octa Phillip Bioscience Managers) today fully endorsed the move by Bioxyne Ltd (ASX:BXN) to acquire Asia Pacific medical device company, Vitality Devices Pty Ltd. Following Bioxyne’s existing product HI-164OV failing to reach clinical trial endpoints last year, BioScience Managers, a 20+% shareholder in BXN, has been at the forefront of […]

Australian Bioscience Fund I to invest in Sea Dragon Marine Oils

IB Australian Bioscience Fund I, managed by Octa Phillip Bioscience Managers (OPBM, formerly IB Managers) has today entered into a conditional Subscription Agreement to invest NZD$2.5 million into Claridge Capital (NZX.CLA) in conjunction with Claridge’s acquisition of SeaDragon Marine Oils. The subscription arrangement is conditional upon the satisfaction of a number of commercial conditions. The […]